Ambrx Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 93
Employees
  • Stock Symbol
  • AMAM
Stock Symbol
  • Share Price
  • $4.58
  • (As of Monday Closing)

Ambrx General Information

Description

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

Contact Information

Website
www.ambrx.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NYS
Primary Office
  • 10975 North Torrey Pines Road La Jolla
  • La Jolla
  • San Diego, CA 92037
  • United States
+1 (858) 000-0000

Ambrx Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ambrx Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.58 $4.51 $4.01 - $22.87 $158M 35M 20.9K -$11.71

Ambrx Financials Summary

In Thousands,
USD 		TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 905,370
Revenue 12,323 13,671 10,311
EBITDA (39,064) (15,922) (20,457)
Net Income (40,118) (16,543) (20,062)
Total Assets 213,725 134,021 61,727
Total Debt 2,410 3,193 4,646
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ambrx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ambrx‘s full profile, request access.

Request a free trial

Ambrx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of enginee
Pharmaceuticals
San Diego, CA
93 As of 2021
00000
0000 0000-00-00
00000000 00000

00000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cul
0000 000000000
Cambridge, United Kingdom
00 As of 0000
00000
000 0000-00-00
0000000000 0 00000

0000000

mmodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fug
0000000000000
Nijmegen, Netherlands
000 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ambrx Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Crescendo Biologics Venture Capital-Backed Cambridge, United Kingdom 00 00000 0000000000 0 00000
0000000 Corporation Nijmegen, Netherlands 000
000000000000 00000 Corporate Backed or Acquired Trevose, PA 00 00000 000000&0 00000
0000000 000 Corporation New York, NY 00 00000 00000000 00000
0000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Ambrx Patents

  • 633

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 22

    Granted

  • 8

    Pending

  • 000

    Expiring in next 12 mo

Ambrx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020223031-A1 Compositions containing, methods and uses of antibody-tlr agonist conjugates Pending 12-Feb-2019 00000000000
CA-3128081-A1 Compositions containing, methods and uses of antibody-tlr agonist conjugates Pending 12-Feb-2019 00000000000
AU-2019361206-A1 Interleukin-10 polypeptide conjugates, dimers thereof, and their uses Pending 19-Oct-2018 00000000000
EP-3867265-A1 Interleukin-10 polypeptide conjugates, dimers thereof, and their uses Pending 19-Oct-2018 00000000000
AU-2019337610-A1 Interleukin-2 polypeptide conjugates and their uses Pending 11-Sep-2018 C07K14/55
To view Ambrx’s complete patent history, request access »

Ambrx Executive Team (15)

Name Title Board Seat Contact Info
Feng Tian Ph.D Chief Executive Officer & Chairman
Sonja Nelson Chief Financial Officer
Dana Zhang Chief Accounting Officer, Accounting & Vice President
Simon Allen Executive
Sukumar Sakamuri Ph.D Vice President & Head of Chemistry
You’re viewing 5 of 15 executive team members. Get the full list »

Ambrx Board Members (22)

Name Representing Role Since
00000 00000 Self Board Member 000 0000
0000 0000 00.0 Ambrx Chief Executive Officer & Chairman 000 0000
000000 0000000 Ambrx Board Member 000 0000
000000 0000 Self Board Member 000 0000
0000 00 Ambrx Board Member 000 0000
You’re viewing 5 of 22 board members. Get the full list »

Ambrx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ambrx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ambrx‘s full profile, request access.

Request a free trial

Ready to get started?

Request a free trial